Disclosed herein are methods for treating a vascular
inflammatory disorder or endothelial
cell disorder using inhibitor compounds that inhibit the expression or
biological activity of Tie-1, Tie-1 endodomain,
thrombin, VEGFR2, VEGFR2 endodomain, EphA2, and any of the cytokines or kinases that are upregulated by activation of Tie-1 or
thrombin, as provided herein. Also disclosed are the use of combinations of inhibitor compounds or the use of an eNOS activator compound in combination with any one or more of the inhibitor compounds. Also disclosed are methods for inhibiting the pro-coagulant activity of
thrombin using a Tie-1 or Tie-1 endodomain inhibitor compound or an EphA2 inhibitor compound. Methods for diagnosing and monitoring vascular inflammatory disorders or endothelial
cell disorders that include the measurement of any of the polypeptides or
nucleic acid molecules of the invention are also disclosed.